Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
BACKGROUND
Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer. Anastrozole treatment is associated with a risk of thromboembolic events and retinal vascular side effects. Herein, we present a case of hemi-central retinal artery occlusion diagnosed in a breast cancer patient using anastrozole.


METHODS
A 53-year-old woman with a hypertensive and diabetic background was admitted to our hospital with breast cancer. Anastrozole treatment was started after surgery, adjuvant chemotherapy, and radiotherapy. Sudden painless loss of vision in the patient's right eye occurred within 13 months of Anastrozole treatment. A fluorescein angiogram revealed hemi-central retinal artery occlusion.


CONCLUSIONS
To the best knowledge of the authors, this is the first report of hemi-central retinal artery occlusion in an anastrozole user.
Karagöz
Bulent
B
Department of Medical Oncology, GATA Haydarpaşa Training Hospital, Istanbul, Turkey. bulentkaragoz1968@yahoo.com
Ayata
Ali
A
Bilgi
Oğuz
O
Uzun
Gunalp
G
Unal
Melih
M
Kandemir
Emin G
EG
Ozgün
Alpaslan
A
Türken
Orhan
O
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use*; D015356:Retinal Artery Occlusion / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole